Kornimate/medical-research-clean huggingface dataset:
latisse (bimatoprost .03% opthalmic solution) for the treatment of hypotrichosis of the eyebrows: latisse versus placebo

Conditions: Hypotrichosis

Summary: the primary purpose of this study is to assess efficacy and safety of latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. the primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the global eyebrow assessment (geya) scale, from baseline to the end of the treatment which will be day 270 period.


Eligibility criteria:
inclusion criteria: * outpatient, female/male subjects of any race, 18-75 years of age. * subjects of childbearing potential must have a negative urine pregnancy test result at baseline and practice a reliable method of contraception throughout the study * patients with hypotrichosis (thinning) of the eyebrows with a geya score of 1 or 2. * patient agrees to abstain from any treatment to the eyebrows including: waxing, plucking, threading, laser hair removal, and/or bleaching (excluding the glabella region). * able to understand the requirements of the study and sign informed consent/hipaa authorization forms. * written informed consent and written authorization for use or release of health and research information obtained. * willing to complete all required study visits, procedures, and evaluations including photography. exclusion criteria: * subjects who are pregnant (positive urine pregnancy test), planning to become pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control. * patients with any uncontrolled systemic disease * patient with any known disease or abnormality of the eyebrows including eczema and seborrheic dermatitis * patients with known or suspected trichotillomania disorder * patients with a history of glaucoma and/or increased ocular pressure * patients who are currently using an iop-lowering prostaglandin analog (including lumigan) * patients with a known hypersensitivity to bimatoprost or any other ingredient in latisse * previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift, eyelid or eyebrow surgery, etc.). * patients with permanent eye and/or eyebrow make-up * any eyebrow tint or dye applications within 2 months prior to study entry * any planned facial cosmetic procedure that would interfere with the evaluation of the eyebrows * participation in another investigational drug or device study within the last 30 days

Keywords: mild moderate
a prospective single arm study of intraoperative radiotherapy for locally advanced or recurrent rectal cancer

Conditions: Malignant Rectal Neoplasm; Recurrent Tumor

Summary: the hypothesis is that intraoperative radiotherapy for locally advanced or recurrent rectal cancer improve outcomes without causing significant side effects.

primary outcome measures are 3-year locoregional control, progression-free and overall survival rates. secondary outcome measures are toxicities scores up to 3 months after surgery (acute) and greater than 3 months after surgery (late). data collected at 3-6 month intervals for 30 months

Eligibility criteria:
inclusion criteria: * locally advanced or recurrent rectal cancer * suitable for radical surgery but at high risk of positive resection margins, * no evidence of metastasis, * age greater than 18 years, * histologically confirmed adenocarcinoma, * ecog performance status \<2. * informed consent exclusion criteria: * unresectable pelvic disease * distant metastasis * significant co-morbidities

Keywords: intraoperative radiotherapy
sjögren's syndrome is associated with meibomian gland dysfunction

Conditions: Meibomian Gland Dysfunction; Sjögren's Syndrome

Summary: the investigators hypothesize that the dry eye caused by ss may include the evaporative type, resulting from the mgd. furthermore, the investigators hypothesize that both pss and sss are associated with mgd.to test our hypothesis, we conducted a prospective clinical study in patients with ss (both pss and sss) and mgd, and the normal population all subjects were matched for both age and gender and assessed for tear function and ocular surface signs and symptoms.


Eligibility criteria:
inclusion criteria: * all the subjects are female and age between 50-60 years * patients with primary ss fulfilled the criteria established by the european study group * patients with sle and ra met the criteria set by the american college of rheumatology exclusion criteria: * the control history of autoimmune disease

Keywords: meibomian gland dysfunction sjögren's syndrome dry eye disease
a study comparing vernakalant therapy to amiodarone therapy in acute management of recent onset atrial fibrillation (af) (mk-6621-055)

Conditions: Atrial Fibrillation

Summary: this study will compare vernakalant therapy to amiodarone therapy in the acute management of recent onset atrial fibrillation.


Eligibility criteria:
inclusion criteria: * symptomatic af (duration of current episode is ≤7 days), which is hemodynamically stable, and participant has no other condition at the time of screening that may result in acute hospitalization * if female and of reproductive potential, the patient agrees to remain abstinent or use 2 acceptable methods of birth control from time of screening until 30-day follow-up. * weigh at least 45 kg * receiving adequate anticoagulant therapy exclusion criteria: * hypersensitivity to the vernakalant or amiodarone or to citric acid, sodium chloride, sodium hydroxide, or iodine * severe aortic stenosis * systolic blood pressure \<100 mmhg * new york heart association (nyha) class iii or iv heart failure * severe bradycardia, sinus node dysfunction, or second and third degree heart block in the absence of a pacemaker * use of iv rhythm control anti-arrhythmics (class i and iii) within 4 hours of study drug administration * acute coronary syndrome (including myocardial infarction) within previous 30 days * history of thyroid dysfunction * severe acute respiratory failure or cardiovascular collapse * participating in another drug study or has received an investigational drug within 30 days prior to enrollment * pregnant or breast-feeding, or expecting to conceive from time of screening until 30-day follow-up
micronutrients in children in critical care with cardiac conditions

Conditions: Heart Defects, Congenital

Summary: this study aims to explore the frequency and types of micronutrient deficiencies in a sample of uk children with chd using standard and novel markers in blood. the study will also explore whether micronutrient deficiencies increase the risk of complications after heart surgery. this study will identify any nutrient deficiencies that need monitoring in clinical practice.

congenital heart disease (chd) is one of the most common birth defects in the uk. children with chd are at risk of underfeeding and undernutrition. this is due to both the increased nutritional requirements of the disease and sometimes clinical management, which often hinders delivery of optimal nutrition.there are as yet no studies assessing micronutrient body stores in children with chd or whether micronutrient deficiencies predict poor clinical outcomes, such as post-operative complications, after major cardiac operations. this study aims to explore the frequency, types and associations of micronutrient deficiencies in children with chd using standard and novel markers in blood. the study will also explore whether micronutrient deficiencies increase the risk of complications after heart surgery. this study will identify any nutrient deficiencies that need monitoring in clinical practice.

Eligibility criteria:
inclusion criteria: * infant or child admitted for elective congenital cardiac surgery at the royal hospital for sick children, glasgow. * aged less than 5 years old exclusion criteria: * infant or child admitted for emergency cardiac surgery * infant or child whose carer with parental responsibility is unable to communicate in english

Keywords: paediatric critical care micronutrients
establishment of genetic basis for neurological disease by genetic screening

Conditions: Neuro-Degenerative Disease

Summary: hereditary neurological disorders are relatively common in paediatric neurological practice, but it has considerable overlap with adult neurological disorders. it is a group of of genetic diseases, most of which with a mendelian inheritance affecting neurological system. pathogenic mechanisms of these diseases are not fully understood. there is currently no effective therapy for most of these diseases. disease-specific and patient- specific ips cells would provide useful source of cells in culture modeling in these diseases. in this study, disease-specific ips cell lines repositories from hereditary neurological disease patients will be established. the cell lines will be registered and make them available to other investigators.

the human ips is generated by direct reprogramming of human somatic cells. these hips cells can give rise to most tissue types in the human embryo and possess many of the properties of human embryonic stem cells (hesc). the big advantage of human ips cell over hesc is that it circumvents most of the limitations of hesc and remains the pluripotency for regeneration of cells and tissues. the unique capacity of self-renewal of ips can provide unlimited supply of pluripotent stem cells for study. the patient-specific ips cell lines should fundamentally eliminate the concern of immune rejection and ethical issues. the disease-specific ips will facilitate the study of the mechanism of nucleotide expansion. it is the ideal medium to study the dynamic changes of the expansion from stem cell stage to different differentiation stages. it also creates a platform for drug development. the establishment of ips stem cells will also make it realistic for target gene replacement/correction therapy. study subjects will be identified at the members from the hong kong spinocerebellar ataxias (sca) association and neurology clinic in prince of wales hospital. patients identify based on the diagnosis, genetic test results and inclusion and exclusion criteria. 10ml blood sample for genetic screening will be collected. skin biopsy will only be scheduled if pathogenic mutation was identified by the genetic screening test and generation of ips is considered necessary to study the pathogenic mechanism of the disease.

Eligibility criteria:
inclusion criteria: 1. individuals at age 18 years or older who have presumed hereditary neurological disease. 2. individuals or his/her guardian who can provide the informed consent. exclusion criteria: 1. individuals who are allergic to local anesthetics. 2. individuals who have serious medical conditions that restrict their ability to tolerate skin biopsy. 3. individuals who have history of bleeding diathesis or use of anticoagulant medications. patients taking nonsteroidal anti-inflammatory agents will be asked to discontinue these medications 3 days prior to skin biopsy.

Keywords: genetic screening neuro-degenerative disease
patient satisfaction and sensory attributes allergic rhinitis nasal spray

Conditions: Allergic Rhinitis

Summary: the study seeks to understand patients' satisfaction and importance of treatment attributes for allergic rhinitis nasal sprays from two brands (ryaltris® vs. dymista®).

the study seeks to understand patients' satisfaction and importance of treatment attributes for allergic rhinitis nasal sprays from two brands (ryaltris® vs. dymista®). to directly compare patient satisfaction with 2 different allergic rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. participants will complete an online survey involving a best-worst scaling (bws) task to determine satisfaction and importance index for sensory attributes. the suggested treatment attributes are informed by a range of previous studies, including those conducted by meltzer et al 2005 and price et al 2020, and methodology from cappre's own work in developing indices for importance and satisfaction of treatment attributes using bws.

Eligibility criteria:
inclusion criteria: allergic rhinitis patients (moderate-to-severe seasonal allergic rhinitis or perennial allergic rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study: * patients above 18 years old * fluent in english * patients initiated on ryaltris® or dymista® nasal spray in the last 12 months and currently using treatment * willing and able to provide consent to participate exclusion criteria: * have reported a loss of taste and/or smell related to covid-19 (or other medical condition) * are employed by a pharmaceutical company (to avoid conflict of interest) * are employed by a vaccine company (to avoid conflict of interest) * do not have access to the internet (to ensure validity of the data) * are unable to read and understand english (to ensure validity of the data)

Keywords: patient preference best-worst scaling treatment attributes
rhd genotype matched red cells for anti-d

Conditions: Sickle Cell Disease; Anti-D Antibodies

Summary: this is a pilot study to evaluate the feasibility and safety of providing rh genotype matched d+ red blood cells (rbcs) to chronically transfused patients with sickle cell disease (scd) who type d+ but have formed anti-d and are currently transfused with d- rbc (red blood cell) units.

red blood cell transfusion remains a critical therapy for patients with sickle cell disease (scd). a major problem is the high rate of alloimmunization (antibody formation against transfused red cells) that occurs in patients with scd. recent studies performed by investigators and others demonstrate rh genetic variants in patients and donors is a major risk factor leading to rh alloimmunization. anti-d formation in d+ patients occurs frequently, and once identified, providing d- cells for all subsequent transfusions can be challenging. these anti-d antibodies in d+ patients suggest exposure to different or variant d protein on donor cells. investigators will test whether transfusion of patients with anti-d with rhd genotyped matched red cells is feasible, safe and can decrease d- donor unit demand.

Eligibility criteria:
inclusion criteria: * subjects age \> 8 years old * diagnosis of scd, all genotypes * require chronic red cell transfusion therapy * history of anti-d * rh genotype predicts d+ expression exclusion criteria: * rare rh genotype that would preclude sufficient rbc units * antigen negative requirements due to alloimmunization that would preclude sufficient rbc units

Keywords: chronic transfusion
substrate ablation in persistent atrial fibrillation for elimination of recurrences (supafer).

Conditions: Persistent and Long Lasting or Chronic Atrial Fibrillation; Atrial Fibrillation Ablation; Linear Left Atrial Ablation; Daily Transtelephonic Electrocardiogram

Summary: antecedents: electrical isolation of pulmonary veins is the standard treatment for patients with atrial fibrillation. however, its efficacy is lower in persistent and chronic forms of this arrhythmia compared to paroxysmal atrial fibrillation. many complementary techniques have been proposed, that added to pulmonary veins isolation, may reduce the recurrence rate of atrial fibrillation. however, none of them has obtained consistent results. linear ablation aims to parcellate and modify the left atrial substrate responsible for atrial fibrillation maintenance. previous studies have offered contradictory results using linear ablation. methods: supafer is a multicenter, 1:1 randomized clinical trial that compares the efficacy of pulmonary veins isolation alone vs pulmonary vein isolation plus an specific protocol of left atrial linear ablation. contrary to previous studies, the specific supafer linear ablation is systematic, homogeneous and target atrial areas that have not been systematically ablated in previous trials. the trial aims at demonstrating the superiority of the combined ablative approach during 1-year follow-up. daily transtelephonic ecg samples a 30 days continuous ecg monitoring are used to maximize de detection of recurrences, even asymptomatic.


Eligibility criteria:
inclusion criteria: * persistent atrial fibrillation documented with electrocardiogram and defined as: persistent (continuous af duration \>1 week) or long-lasting persistent (continuous af duración \>1 year). * one of the following additional criteria: 1)symptomatic af, 2)recurrence despite antiarrhythmic drugs or after electrical cardioversion, 3)tachymiopathy, 4)heart failure, 5)antiarrhythmic drugs either not tolerated or rejected or considered inadequate by the patient or an electrophysiology specialist, 6)preference for ablation explicitly manifested by the patient. * age \>=18 years and written informed consent. exclusion criteria: * af with a reversible cause. * previous pulmonary veins isolation or left atrial linear ablation. * cardiac surgery, acute coronary syndrome, percutaneous coronary intervention o ischaemic stroke \<1 month before ablation. * intracranial haemorrhage \<3 months before ablation. * ablation contraindicated due to 1)absolute contraindication for oral anticoagulants, 2)persistent atrial thrombus, 3)pregnancy, 4)extreme fragility and 5)life expectancy \<1 year.
a pilot randomized, double-blind, placebo-controlled, parallel design, multicenter trial to evaluate the effect of ranitidine on immunologic indicators in asymptomatic hiv-1 infected subjects with a cd4 cell count between 400-700 cells/mm3

Conditions: HIV Infections

Summary: to evaluate the effect of ranitidine on immunologic indicators in asymptomatic hiv-1 infected patients with cd4 counts of 400-700 cells/mm3.

patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.

Eligibility criteria:
inclusion criteria patients must have: * asymptomatic hiv-1 infection. * cd4 count of 400-700 cells/mm3. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * significant illness. * acute illness at randomization. * hemodialysis. prior medication: excluded: * antiretroviral use within 60 days prior to study entry.

Keywords: ranitidine
lifestyle intervention for weight gain management for patients with schizophrenia

Conditions: Schizophrenia; Obesity

Summary: the aims of this study were to evaluate the efficacy of an intervention for weight gain management for patients from schizophrenia spectrum compared to treatment as usual (tau), and to evaluate the effects of this program on metabolic profile, symptoms and quality of life.

the study took place on four institutions: schizophrenia program (proesq- universidade federal de são paulo), schizophrenia program of institute of psychiatry projesq (universidade de são paulo), caism (centro de atenção integrada à saúde mental) from irmandade santa casa de misericórdia de são paulo, and caps luiz da rocha cerqueira, all in the city of são paulo. participants were randomly assigned to an intervention group or a standard care group using table of randomization from web site www.randomization.com. the patients' weights were recorded monthly. all patients were weighed in the morning, on the same scale, without shoes, with the individuals wearing light clothes. waist was considered at the level of the navel. measures were collected by the same investigator in all assessments. body mass index (bmi) was calculated as the weight in kilograms divided by the square of the height in meters. the investigators recorded sociodemographic data, clinical data and physical exam (weight, height, bmi, waist circumference and blood pressure). patients were diagnosed as having schizophrenia by the scid-p (ref). severity of the disease was assessed using panss, calgary depression scale, cgi-s and cgi-i. gaf, ilss-br, and he following self-rated scales: whoqol-bref, rosenberg self-esteem scale, ipaq, dine and fagerstrom were used to evaluate functionality (gaf), independent living skills (ilss-br), quality of life (whoqol-bref), self esteem (rosenberg self-esteem scale), physical activity (ipaq- short version), fat and fibers ingestion (dine), and smoking (fagerstrom). raters were kept blind for patient's treatment condition. fasting glucose, total cholesterol, hdl, ldl, triglycerides, insulin, and homa-ir index were assessed at baseline, and 3 months.

Eligibility criteria:
inclusion criteria: * eligible patients were between 18 and 65 years of age, * were on an antipsychotic medication, * were asymptomatic (panss ≤ 60), * had outpatient status and a dsm-iv diagnosis of schizophrenia, * schizoaffective disorder or other psychosis, and * presented some interest on themes of program. exclusion criteria: * a history of diabetes mellitus, * eating disorders (anorexia and bulimia), * drug or alcohol abuse, * and an acute psychotic state in need of intensive management. * there was no use of medication for weight control for the subjects during the intervention and follow-up period.

Keywords: schizophrenia weight gain intervention
retinal nerve fibres layers thickness study in glaucomatous patients

Conditions: Glaucoma

Summary: in this study the investigators are going to study the retinal nerve fibers layers (rnfl) modification of two groups of patients, one taking no drugs, the other taking forskolin, rutin and vitamins b1 and b2.


Eligibility criteria:
inclusion criteria: * age (30-80 years); * baseline intraocular pressure (iop) (20-32 mmhg): average untreated intra ocular pressure (iop) for both eyes as determined from 2 to 4 visits within a 6-months period; * central corneal thickness (cct) (475-650 µm): average of 3 different measurements from both eyes during the same visit; * pattern standard deviation (psd) (0,50-3,00 db) average of both eyes as stated on the most recent visual field index report * vertical cup/disk ratio (0,00-0,80): average of both eyes * all these data were entered into a calculator specially designed for star (scoring tool for assessing risk) ii parameter. the patients were divided into low-, moderate- and high risk groups according to the result given by the calculator. exclusion criteria: -other ocular pathologies than glaucoma
efficacy and safety of teneligliptin in chinese patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: this study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of mp-513 (teneligliptin).


Eligibility criteria:
inclusion criteria: * a signed and dated informed consent form has been obtained from the subject, in accordance with international conference on harmonisation guidelines on good clinical practice (ich gcp), before any screening or study related procedures take place. * the subject is aged ≥18 years at signature of the informed consent form. * hospitalization status: outpatient. * the subject has had a documented diagnosis of type 2 diabetes mellitus for at least 3 months at the screening visit (day -28). * the subject is undergoing diet and exercise therapy, and diet and exercise regimen has not been changed for at least 8 consecutive weeks at the screening visit (day -28). subjects who cannot do exercise due to complication are not limited to this criteria. * the subject's glycosylated fraction of haemoglobin(hba1c) is ≥ 7.0% and \< 10.0% at the screening visit (day -28) and on day -14. exclusion criteria: * the subject has a history of type 1 diabetes mellitus or a secondary form of diabetes. * the subject has received insulin within 1 year prior to the screening visit (day -28), with the exception of insulin therapy during hospitalization or insulin therapy for medical conditions not requiring hospitalization (\< 2 weeks' duration). * the subject has received an anti-diabetic drug within 8 weeks prior to the screening visit (day -28).